Clinical trials with medicinal products (CTR)
Specific rules for the submission, assessment and conduct of clinical trials with medicinal products are set out in the EU Clinical Trial Regulation 536/2014 (CTR). The CTR applies in the European Union as of 31 January 2022.
The Clinical Trials Coordination and Advisory Group (CTAG) of the European Commission published a Quick guide for sponsors and investigators on the CTR and the submission of a clinical trial application: Quick guide on the rules and procedures of the CTR.
List of abbreviations
Abbreviation | Explanation |
---|---|
AMS | Additional Member State |
ATMP | Advanced Therapy Medicinal Product. An ATMP is defined as either a gene therapy ‘medicinal product’ (GTMP), a somatic cell therapy ‘medicinal product’ (sCTMP) or a tissue-engineered product (TEP) |
AxMP | Auxiliary Medicinal Product |
CTIS | Clinical Trial Information System (EU portal and database) |
CTR | Clinical Trial Regulation EU No. 536/2014 |
CCMO | Central Committee on Research involving Human Subjects |
CCMO_NCTO | National Clinical Trial Office - CCMO |
cMS | Member State Concerned |
EEA | European Economic Area (European Union plus Iceland, Liechtenstein and Norway) |
EMA | European Medicines Agency |
EU | European Union |
ICF | Informed Consent Form |
IMP | Investigational Medicinal Product |
LVLP | Last Visit Last Patient |
MREC | accredited Medical Research Ethics Committee |
MS | Member State |
MSC | Member State Concerned |
PIP | Pediatric Investigation Plan |
RMS | Reporting Member State |
RSI | Reference Safety Information |
saMS | Safety assessing Member State |
SIS | Subject Information System |
WMO | Dutch Act on Medical Research Involving Human Subjects |